Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)

Market Cap	3.84B -19.2%
Revenue (ttm)	2.46B +1.9%
Net Income	21.02M
EPS	0.04
Shares Out	438.41M
PE Ratio	218.58
Forward PE	30.17
Dividend	0.30 (3.43%)
Ex-Dividend Date	Sep 11, 2026

Volume	12,327,853
Open	8.40
Previous Close	8.39
Day's Range	8.40 - 8.87
52-Week Range	7.89 - 14.37
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About SHA:603520

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium, and iohexol injections; contrast agent APIs and intermediates consisti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 1,905
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603520

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error